The stability of the U230(VI)-DCP chelate complex was monitored for up to 84 days (4 half-lives of U230) in human blood serum. No release of uranium from the chelate complex was observed. Our in vitro findings indicate that DCP is a promising candidate for chelation of the novel therapeutic alpha emitter 230U under physiological conditions. Presented at 21st Annual Congress of the EANM, 15-18 October 2008, Munich, Germany, section Radiopharmacy/Radiopharmaceuticals: Therapy & Miscellaneous
COBISS.SI-ID: 22351399